Rapid analyzing mixed STR profiles based on the global minimum residual method.

The analysis of mixed short tandem repeat (STR) profiles has been long considered as a difficult challenge in the forensic DNA analysis. In the context of China, the current approach to analyze mixed STR profiles depends mostly on forensic manual method. However, besides the inefficiency, this technique is also susceptible to subjective biases in interpreting analysis results, which can hardly meet up with the growing demand for STR profiles analysis. In response, this study introduces an innovative method known as the global minimum residual method, which not only predicts the proportion of each contributor within a mixture, but also delivers accurate analysis results. The global minimum residual method first gives new definitions to the mixture proportion, then optimizes the allele model. After that, it comprehensively considers all loci present in the STR profile, accumulates and sums the residual values of each locus and selects the mixture proportion with the minimum accumulative sum as the inference result. Furthermore, the grey wolf optimizer is also employed to expedite the search for the optimal value. Notably, for two-person STR profiles, the high accuracy and remarkable efficiency of the global minimum residual method can bring convenience to realize extensive STR profile analysis. The optimization scheme established in this research has exhibited exceptional outcomes in practical applications, boasting significant utility and offering an innovative avenue in the realm of mixed STR profile analysis.

Pioneer factor ETV2 safeguards endothelial cell specification by recruiting the repressor REST to restrict alternative lineage commitment.

Mechanisms of cell fate specification remain a central question for developmental biology and regenerative medicine. The pioneer factor ETV2 is a master regulator for the endothelial cell (EC) lineage specification. Here, we studied mechanisms of ETV2-driven fate specification using a highly efficient system in which ETV2 directs human induced pluripotent stem cell-derived mesodermal progenitors to form ECs over two days. By applying CUT&RUN, single-cell RNA-sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) analyses, we characterized the transcriptomic profiles, chromatin landscapes, dynamic cis-regulatory elements (CREs), and molecular features of EC cell differentiation mediated by ETV2. This defined the scope of ETV2 pioneering activity and identified its direct downstream target genes. Induced ETV2 expression both directed specification of endothelial progenitors and suppressed acquisition of alternative fates. Functional screening and candidate validation revealed cofactors essential for efficient EC specification, including the transcriptional activator GABPA. Surprisingly, the transcriptional repressor REST was also necessary for efficient EC specification. ETV2 recruited REST to occupy and repress non-EC lineage genes. Collectively, our study provides an unparalleled molecular analysis of EC specification at single-cell resolution and identifies the important role of pioneer factors to recruit repressors that suppress commitment to alternative lineages.

Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease.

Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by elevated motor behaviors and dream enactments in REM sleep, often preceding the diagnosis of Parkinson's disease (PD). As RBD could serve as a biomarker for early PD developments, pharmacological interventions targeting α-synuclein aggregation triggered RBD could be applied toward early PD progression. However, robust therapeutic guidelines toward PD-induced RBD are lacking, owing in part to a historical paucity of effective treatments and trials. We reviewed the bidirectional links between α-synuclein neurodegeneration, progressive sleep disorders, and RBD. We highlighted the correlation between RBD development, α-synuclein aggregation, and neuronal apoptosis in key brainstem regions involved in REM sleep atonia maintenance. The current pharmacological intervention strategies targeting RBD and their effects on progressive PD are discussed, as well as current treatments for progressive neurodegeneration and their effects on RBD. We also evaluated emerging and potential pharmacological solutions to sleep disorders and developing synucleinopathies. This review provides insights into the mechanisms and therapeutic targets underlying RBD and PD, and explores bidirectional treatment effects for both diseases, underscoring the need for further research in this area.